Legal Representation
Attorney
John L. DuPre'
USPTO Deadlines
Application History
17 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 2, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Oct 1, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Oct 1, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Jun 12, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 12, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 12, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 10, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 17, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jan 17, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jan 17, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Nov 8, 2022 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Nov 8, 2022 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | Loading... |
| Nov 3, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 3, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Nov 3, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Aug 29, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 27, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical, medical and clinical preparations for use in cell and gene therapy; pharmaceutical, medical and clinical preparations for use in cell and gene therapy for treatment of cancer and genetic diseases; Cell and gene therapy vectors for treatment of cancer and genetic diseases; therapeutic preparations for enhancing the targeting, delivery, and effectiveness of cancer treatments; t-cells for medical and therapeutic use; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer and genetic diseases; pharmaceutical and biological preparations based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in human therapeutics, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cancer and genetic diseases
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Scientific and medical research services in the field of cell and gene therapies; Scientific and medical research services in the field of cell and gene therapies using engineered viral vectors
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
042